Biology Reference
In-Depth Information
64. Cummings M, Higginbottom K, McGurk CJ, et al. XPA versus
ERCC1 as chemosensitising agents to cisplatin and mitomycin
C in prostate cancer cells: role of ERCC1 in homologous
recombination repair.
Biochem Pharmacol
2006;
assay
for HCV NS3
helicase
activity.
Antiviral Res
93.
77. Belon CA, Frick DN. Monitoring helicase activity with molec-
ular beacons.
Biotechniques
2008;
2000;
(3):181
46
e
75.
65. Graf N, Ang WH, Zhu G, Myint M, Lippard SJ. Role of Endo-
nucleases XPF and XPG in nucleotide excision repair of plati-
nated DNA and cisplatin/oxaliplatin cytotoxicity.
Chembiochem
2011;
(2):166
72
e
40, 442.
78. Selby CP, Sancar A. Molecular mechanism of transcription-
repair coupling [see comments].
Science
1993;
45
(4):433
e
(5104):53
8.
260
e
79. Buratowski S. DNA repair and transcription:
the helicase
23.
66. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC.
Enhanced cisplatin cytotoxicity by disturbing the nucleotide
excision repair pathway in ovarian cancer cell lines.
Cancer Res
2003;
(7):1115
12
e
8.
80. Schaeffer L, Roy R, Humbert S, et al. DNA repair helicase:
a component of BTF2 (TFIIH) basic transcription factor.
Science
1993;
connection.
Science
1993;
(5104):37
260
e
63.
81. Fan L, Arvai AS, Cooper PK, Iwai S, Hanaoka F, Tainer JA.
Conserved XPB core structure and motifs for DNA unwinding:
implications for pathway selection of transcription or excision
repair.
Mol Cell
2006;
(5104):58
260
e
6.
67. Balin-Gauthier D, Delord JP, Pillaire MJ, et al. Cetuximab
potentiates oxaliplatin cytotoxic effect through a defect in NER
and DNA replication initiation.
Br J Cancer
2008;
(6):1311
63
e
8.
68. Prewett M, Deevi DS, Bassi R, et al. Tumors established with
cell lines selected for oxaliplatin resistance respond to oxali-
platin if combined with cetuximab.
Clin Cancer Res
2007;
(1):120
98
e
37.
82. Fan L, Fuss JO, Cheng QJ, et al. XPD helicase structures and
activities: insights into the cancer and aging phenotypes from
XPD mutations.
Cell
2008;
(1):27
22
e
13
(24):
800.
83. Glanzer JG, Liu S, Oakley GG. Small molecule inhibitor of the
RPA70 N-terminal protein interaction domain discovered using
in silico and in vitro methods.
Bioorg Med Chem
2011;
(5):789
133
e
40.
69. Yacoub A, McKinstry R, Hinman D, Chung T, Dent P,
Hagan MP. Epidermal growth factor and ionizing radiation up-
regulate the DNA repair genes XRCC1 and ERCC1 in DU145
and LNCaP prostate carcinoma through MAPK signaling.
Radiat Res
2003;
7432
e
19
(8):
95.
84. Haring SJ, Mason AC, Binz SK, Wold MS. Cellular functions of
human RPA1. Multiple roles of domains in replication, repair,
and checkpoints.
J Biol Chem
2008;
2589
e
52.
70. O'Donovan A, Scherly D, Clarkson S, Wood R. Isolation of
active recombinant XPG protein, a human DNA repair endo-
nuclease.
J Biol Chem
1994;
159
(4):439
e
111.
85. Hass CS, Gakhar L, Wold MS. Functional characterization of
a cancer causing mutation in human replication protein A.
Mol
Cancer Res
2010;
283
(27):19095
e
8.
71. Riedl T, Hanaoka F, Egly JM. The comings and goings of
nucleotide excision repair factors on damaged DNA.
EMBO J
2003;
:15965
269
e
26.
86. Turchi JJ, Shuck SC, Short EA, Andrews BJ. Targeting nucleotide
excision repair as a mechanism to increase cisplatin efficacy. In:
Bonetti A, Leone R, Muggia FM, Howell SB, editors.
Platinum
and other heavy metal compounds in cancer chemotherapy
. New
York: Humana Press; 2009. p. 177
8
(7):1017
e
303.
72. Wakasugi M, Reardon JT, Sancar A. The non-catalytic function
of XPG protein during dual incision in human nucleotide
excision repair.
J Biol Chem
1997;
(19):5293
22
e
4.
73. Walsh CS, Ogawa S, Karahashi H, et al. ERCC5 is a novel
biomarker of ovarian cancer prognosis.
J Clin Oncol
2008;
(25):16030
272
e
88.
87. Andrews BJ, Turchi JJ. Development of a high-throughput
screen for inhibitors of replication protein A and its role in
nucleotide excision repair.
Mol Cancer Ther
2004;
e
(18):
26
8.
74. Stevens EV, Nishizuka S, Antony S, et al. Predicting cisplatin
and trabectedin drug sensitivity in ovarian and colon cancers.
Mol Cancer Ther
2008;
2952
e
91.
88. Shuck SC, Turchi JJ. Targeted inhibition of Replication Protein A
reveals cytotoxic activity, synergy with chemotherapeutic DNA-
damaging agents, and insight into cellular function.
Cancer Res
2010;
3
(4):385
e
8.
75. Sun X, Li F, Sun N, et al. Polymorphisms in XRCC1 and XPG
and response to platinum-based chemotherapy in advanced
non-small cell
(1):10
7
e
98.
89. Neher TM, Shuck SC, Liu J, Zhang JT, Turchi JJ. Identification of
novel small molecule inhibitors of the XPA protein using in
silico based screening.
ACS Chem Biol
2010;
70
(8):3189
e
lung cancer patients.
Lung Cancer
2009;
(2):
65
6.
76. Hicham Alaoui-Ismaili M, Gervais C, Brunette S, Gouin G,
Hamel M, Rando RF, et al. A novel high throughput screening
230
e
5
(10):953
e
65.
